Key Highlights

  • VERAXA Biotech, a clinical-stage oncology company, is trading up 21.30% to $1.31 in Wednesday's session.
  • The company detailed its implementation of FDA-aligned New Approach Methodologies across its preclinical pipeline.
  • An ex vivo panel using patient-derived tumor models required about 10 mice, versus an estimated 200 or more for comparable in vivo studies.
  • Shares remain within a wide 52-week range of $1.04 to $27.36 following the company's June 2026 IPO.

New Testing Approach Draws Fresh Investor Attention

VERAXA Biotech AG (NASDAQ:VRXA), a Zurich-based oncology company developing antibody-based cancer therapies, is trading sharply higher in Wednesday's session after detailing how it is implementing FDA-aligned New Approach Methodologies across its preclinical research programs. The company said the approach could accelerate clinical advancement of its pipeline while significantly reducing reliance on animal testing, positioning it ahead of a 2025 FDA roadmap encouraging the phased replacement of traditional animal models.

The company's Chief Scientific Officer said the shift reflects both a regulatory alignment and a scientific opportunity, allowing the firm to generate more clinically predictive data while moving faster through development.

Patient-Derived Models Replace Hundreds of Animal Subjects

The company evaluated its lead BiTAC-based T cell engager and bispecific antibody-drug conjugate candidates using an ex vivo panel of ten low-passage, patient-derived tumor models of non-small cell lung cancer. Because the assays can be split into many parallel samples from a small number of donor mice, the panel required only about ten mice in total, compared with an estimated 200 or more needed for comparable in vivo efficacy studies. Across the panel, the combined therapy candidate consistently induced potent T cell-mediated tumor cell killing, while control treatments showed only minimal activity.

Pipeline Validation Still Ahead of Clinical Development

The company is building a pipeline of next-generation antibody-based cancer therapeutics, including bispecific T cell engagers and antibody-drug conjugates, founded on research originating at the European Molecular Biology Laboratory. With shares having traded as low as $1.04 and as high as $27.36 since its June IPO, the stock continues to show the Volatility typical of early-stage biotechnology companies still advancing toward clinical-stage validation. The next milestones investors are likely to watch are whether the preclinical data translates into IND-enabling studies and eventual clinical trial starts.